New hope for glioblastoma? early trial combines drug with radiation

NCT ID NCT04555577

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-phase trial tests a new drug called Peposertib, combined with radiation and chemotherapy, for people with a hard-to-treat type of brain cancer called glioblastoma. The study aims to find the best dose and check safety in 29 participants. If it works, the drug may help radiation kill cancer cells more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Peposertib (a DNA-PK inhibitor drug)
What this could lead to: If successful, this could point toward a new treatment option for glioblastoma that is resistant to standard chemotherapy.
What could go wrong: This is a very early Phase I trial with only 29 participants, so it is primarily testing safety and dosing. It may not lead to an effective treatment, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOSARCOMA

Contacts and locations

Show contact details

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.